Shigella case isolates from the Global Enteric Multicenter Study were serotyped to guide vaccine development. A quadrivalent vaccine that includes O antigens from S. sonnei, S. flexneri 2a, S. flexneri 3a, and S. flexneri 6 should provide broad protection.
Keywords: serotyping, Shigella, shigellosis, vaccines
Abstract
Background. Shigella, a major diarrheal disease pathogen worldwide, is the target of vaccine development. The Global Enteric Multicenter Study (GEMS) investigated burden and etiology of moderate-to-severe diarrheal disease in children aged <60 months and matched controls without diarrhea during 3 years at 4 sites in Africa and 3 in Asia. Shigella was 1 of the 4 most common pathogens across sites and age strata. GEMS Shigella serotypes are reviewed to guide vaccine development.
Methods. Subjects' stool specimens/rectal swabs were transported to site laboratories in transport media and plated onto xylose lysine desoxycholate and MacConkey agar. Suspect Shigella colonies were identified by biochemical tests and agglutination with antisera. Shigella isolates were shipped to the GEMS Reference Laboratory (Baltimore, MD) for confirmation and serotyping of S. flexneri; one-third of isolates were sent to the Centers for Disease Control and Prevention for quality control.
Results. Shigella dysenteriae and S. boydii accounted for 5.0% and 5.4%, respectively, of 1130 Shigella case isolates; S. flexneri comprised 65.9% and S. sonnei 23.7%. Five serotypes/subserotypes comprised 89.4% of S. flexneri, including S. flexneri 2a, S. flexneri 6, S. flexneri 3a, S. flexneri 2b, and S. flexneri 1b.
Conclusions. A broad-spectrum Shigella vaccine must protect against S. sonnei and 15 S. flexneri serotypes/subserotypes. A quadrivalent vaccine with O antigens from S. sonnei, S. flexneri 2a, S. flexneri 3a, and S. flexneri 6 can provide broad direct coverage against these most common serotypes and indirect coverage against all but 1 (rare) remaining subserotype through shared S. flexneri group antigens.
(See the Editorial Commentary by Van de Verg and Venkatesan on pages 942–3.)
The Global Enteric Multicenter Study (GEMS) of the burden and etiology of moderate-to-severe diarrheal illness (MSD) in children aged <5 years performed over 3 years at 4 sites in sub-Saharan Africa (Basse, The Gambia; Bamako, Mali; Siaya County, Kenya; Manhiça, Mozambique) and 3 in South Asia (Karachi, Pakistan; Kolkata, India; Mirzapur, Bangladesh) established Shigella as 1 of 4 top pathogens [1]. The increased diagnostic yield observed when stool specimens are examined using gel-based or quantitative real-time polymerase chain reaction (PCR) suggests that the burden of disease may be greater than estimated using standard cultures [2, 3]. Although pediatric morbidity from shigellosis remains substantial, mortality has diminished, in part, because of the virtual disappearance worldwide of the highly virulent Shiga toxin-producing S. dysenteriae 1 serotype and because World Health Organization guidelines recommend antibiotic treatment for clinical dysentery (diarrhea with gross blood). Regrettably, Shigella relentlessly acquires resistance to antibiotics that were previously effective in diminishing disease severity and duration and pathogen excretion [2, 4].
Based on clinical severity, disease burden, and emergence of antimicrobial resistance, Shigella is a prime target for vaccine development [2, 4–6]. The 4 species (also called groups or subgroups) of Shigella encompass 50 serotypes and subserotypes that include the following: S. dysenteriae (15 serotypes); S. flexneri (15 serotypes and subserotypes, including S. flexneri 1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6, X, and Y and 2 new subserotypes 7a and 7b, previously referred to as Shigella provisional 88–893, Y394, or “S. flexneri 1c” [7]); S. boydii (19 serotypes); and S. sonnei (1 serotype). The distinct serotypes/subserotypes are defined by conformational epitopes of their O polysaccharide antigens [6]. Challenge/rechallenge studies in nonhuman primates [8] and volunteers [9–11], epidemiological field studies [12], and seroepidemiological studies [13, 14] indicate that clinical infection with wild type Shigella strains bestows approximately 75% subgroup-specific (and usually subserotype-specific) immunity. Live oral vaccines [15–18] and O-polysaccharide-protein conjugate vaccines [19, 20] that have conferred protection in randomized controlled field trials corroborate the importance of immune responses to Shigella O antigens. Most Shigella vaccines in clinical development are based on eliciting protection against multiple epidemiologically important serotypes. Accordingly, to rationally guide vaccine formulation, it is imperative to have robust data on the distribution of Shigella serotypes associated with shigellosis. GEMS serotype data provide such information from the geographic areas where 80% of deaths due to diarrheal disease among young children occur [1, 21].
MATERIALS AND METHODS
Conducted over 3 years, GEMS was an age-stratified, matched case-control study of MSD among children aged 0–59 months residing in censused populations and seeking care at medical facilities serving 7 sites in sub-Saharan Africa and South Asia. Rationale for the GEMS and detailed clinical, epidemiologic, and microbiological methods have been published elsewhere [21–24].
Epidemiological and Clinical Methods
The University of Maryland, Baltimore Institutional Review Board and ethics committees at each field site approved the protocol. A censused population provided the sampling frame at each study site where sentinel hospitals or health centers serving the population enrolled cases from 3 age strata: infants (0–11 months), toddlers (12–23 months), and young children (24–59 months) [1, 24]. Age-eligible children from the censused population visiting the centers with diarrhea (≥3 loose stools in the previous 24 hours) were examined for eligibility. To be included, the child's diarrheal episode had to be new (onset after ≥7 diarrhea-free days), acute (duration <7 days), and had to meet at least 1 of the following criteria defining MSD: clinical evidence of moderate-to-severe dehydration (sunken eyes, loss of skin turgor, or initiation of intravenous fluids based on clinical judgment); dysentery; or clinical judgment that the child with diarrheal illness needed to be hospitalized. For each MSD case, 1–3 (occasionally 4) controls without diarrhea, randomly selected from each site's census database and matched by age, gender, and residential community, were enrolled within 14 days of the matched index case.
Upon enrollment, each case and matched control provided a stool specimen (≥3 grams) that, within 1 hour of passage, was stored cold until delivered to the laboratory. If antibiotics were to be administered to patients before stool was produced, 2 rectal swabs were obtained for bacterial culture pending passage of whole stool for the remaining assays.
Bacteriologic Methods
Stool samples/rectal swabs were introduced into Cary–Blair and buffered glycerol saline (BGS) transport media, the latter to enhance yield of Shigella [22, 25]; inoculation onto solid media occurred within 18 hours. To isolate Shigella, the BGS swab was plated onto MacConkey and xylose lysine desoxycholate agar. After incubation at 37°C, suspicious colonies were subjected to biochemical tests [22]. Shigella isolates at the field sites were serotyped with polyvalent group A, B, C, and D antisera (Denka Seiken Co., Ltd., Tokyo, Japan or Reagensia AB, Solna, Sweden) and shipped to the GEMS Reference Laboratory at the Center for Vaccine Development (CVD) for confirmation and identification of individual S. flexneri serotypes/subserotypes and S. dysenteriae 1. One-third of isolates serotyped at CVD were sent to the Centers for Disease Control and Prevention (CDC) for serotype confirmation.
Chromosomal genes encoding Shigella enterotoxin 1 (ShET1) [26, 27] were amplified by PCR using the following primers:
set1AForward: 5′- CAG CGT CTT TCA GCG ACA GTG TTT -3′
set1AReverse: 5′- AGC ATG ATA CTC AAC AGC CAG ACC -3′
set1BForward: 5′- ATA CTG GCT CCT GTC ATT CAC GGT -3′
set1BReverse: 5′- GGA AGT GAC AGG GCA TTT GTG GAT -3′ [28, 29].
Statistical Methods
Distributions of species were compared by χ2 test with 3 degrees of freedom. Individual species and subserotypes were compared using χ2 test with no continuity correction or 2-sided Fisher exact test. P ≤ .05 was considered statistically significant.
RESULTS
We investigated 1130 Shigella isolates from cases (1120 from the matched case-control dataset [1] and 10 from MSD cases for whom there was no control) and 219 isolates from controls without diarrhea; 11 other isolates from the sites (9 cases and 2 controls) were not sent to CVD. The distribution of Shigella species among case isolates is shown in Table 1. Only 5.0% of case isolates (N = 56) were S. dysenteriae (none were S. dysenteriae 1) and 5.4% (N = 61) were S. boydii. Overall, 89.6% of case isolates were S. flexneri (N = 745; 65.9%) or S. sonnei (N = 268; 23.7%). Four serotypes/subserotypes, S. flexneri 2a, S. flexneri 2b, S. flexneri 3a, and S. flexneri 6, comprised 581 of the 745 S. flexneri isolates (78.0%; Table 1); inclusion of S. flexneri 1b raises the total to 89.4% of all S. flexneri.
Table 1.
Species and Serotype Distribution by Site of 1130 Shigella Isolates From Children Aged <60 Months With Moderate to Severe Diarrhea in the Global Enteric Multicenter Study and of 219 Isolates From Control Children Without Diarrhea
| Cases |
Controls |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Serogroup, Serotype, or Subserotype | All 7 GEMS Sites | 6 GEMS Sites Other Than Bangladesh | Bangladesh | Pakistan | India | Gambia | Mali | Kenya | Mozambique | All 7 GEMS Sites |
| Total isolates | 1130 | 519 | 611 | 129 | 91 | 116 | 41 | 105 | 37 | 219 |
| Shigella dysenteriae | 56 (5.0%)a | 33 (6.4%)b | 23 (3.8%)c | 6 (4.7%)c | 2 (2.2%)c | 5 (4.3%)c | 1 (2.4%)c | 19 (18.1%)c | 0 | 10 (4.6%) |
| S. boydii | 61 (5.4%)a | 37 (7.1%)b | 24 (3.9%) | 10 (7.8%) | 10 (11.0%) | 7 (6.0%) | 2 (4.9%) | 6 (5.7%) | 2 (5.4%)c | 24 (11.0%) |
| S. sonneid | 268 (23.7%)a | 119 (22.9%)b | 149 (24.4%) | 29 (22.5%) | 32 (35.2%) | 24 (20.7%) | 12 (29.3%) | 17 (16.2%) | 5 (13.5%) | 70 (32.0%) |
| S. flexneri | 745 (65.9%)a | 330 (63.6%)b | 415 (67.9%) | 84 (65.1%) | 47 (51.7%) | 80 (69.0%) | 26 (63.4%) | 63 (60.0%) | 30 (81.1%) | 115 (52.5%) |
| S. flexnerid serotypes/subserotypes | ||||||||||
| 1a | 3 (0.3%)a | 1 (0.2%)b | 2 (0.3%)c | 1 (0.8%)c | 0 | 0 | 0 | 0 | 0 | 0 |
| 1b | 85 (7.5%)a | 55 (10.6%) | 30 (4.9%) | 12 (9.3%) | 1 (1.1%)c | 15 (12.9%)c | 8 (19.5%)c | 15 (14.3%)c | 4 (10.8%)c | 19 (8.7%) |
| 2a | 228 (20.2%)a | 101 (19.5%) | 127 (20.8%) | 21 (16.3%) | 24 (26.4%) | 35 (30.2%) | 5 (12.2%) | 2 (1.9%) | 14 (37.8%) | 21 (9.6%) |
| 2b | 123 (10.9%)a | 12 (2.3%) | 111 (18.2%) | 0 | 0 | 4 (3.5%) | 4 (9.8%) | 4 (3.8%) | 0 | 9 (4.1%) |
| 3a | 106 (9.4%)a | 47 (9.0%) | 59 (9.7%) | 12 (9.3%) | 11 (12.1%) | 5 (4.3%) | 2 (4.9%) | 14 (13.3%) | 3 (8.1%) | 17 (7.8%) |
| 3b | 1 (0.1%)a | 0 | 1 (0.2%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4a | 33 (2.9%)a | 19 (3.7%) | 14 (2.3%) | 9 (7.0%) | 4 (4.4%) | 0 | 1 (2.4%) | 5 (4.8%) | 0 | 6 (2.7%) |
| 4b | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5b | 3 (0.3%)a | 0 | 3 (0.5%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.5%) |
| 6 | 124 (11.0%)a | 70 (13.5%) | 54 (8.9%) | 23 (17.8%) | 5 (5.5%) | 12 (10.3%) | 4 (9.8%) | 19 (18.1%) | 7 (18.9%) | 35 (16.0%) |
| 7ae | 23 (2.0%)a | 13 (2.5%) | 10 (1.6%) | 6 (4.7%) | 2 (2.2%) | 1 (0.9%) | 0 | 4 (3.8%) | 0 | 6 (2.7%) |
| 7be | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| X | 11 (1.0%)a | 11 (2.1%) | 0 | 0 | 0 | 7 (6.0%) | 2 (4.9%) | 0 | 2 (5.4%) | 1 (0.5%) |
| Y | 5 (0.4%)a | 1 (0.2%) | 4 (0.7%) | 0 | 0 | 1 (0.9%) | 0 | 0 | 0 | 0 |
The distribution of species among the Bangladesh isolates was significantly different (P = .015) from the composite of the other 6 GEMS sites. The percentage of the various S. flexneri serotypes and subserotypes isolated in Bangladesh was significantly different from the percentage at the other 6 sites for the greater percentage of S. flexneri 2b in Bangladesh (P < .0001) and the lower percentages of S. flexneri 1b (P = .0003), S. flexneri 6 (P = .015), and S. flexneri X (P = .0002).
Abbreviation: GEMS, Global Enteric Multicenter Study.
a Percent of all 1130 case isolates from the composite of all 7 sites.
b Percent of the total 519 case isolates from the 6 GEMS sites other than Bangladesh.
c Percent of the total isolates from the individual GEMS site.
d Bolded S. flexneri serotypes/subserotypes are those proposed for inclusion, along with S. sonnei, in a quadrivalent broad-spectrum Shigella vaccine.
e S. flexneri 7 strains were previously referred to as Shigella “provisional 88–893,” “provisional Y394,” or “S. flexneri 1c.”
Mirzapur, Bangladesh, where shigellosis exhibits a striking seasonal peak [30], contributed the most Shigella cases. Thus, it was important to compare Bangladesh serotype data with data from the other 6 GEMS sites (Table 1). The overall species distributions in Bangladesh and the other sites combined were significantly different (P = .015), but the absolute differences for individual species were modest. Percentages of the 2 most prevalent species, S. flexneri and S. sonnei, were similar and not significantly different in Bangladesh vs the combined other sites. The percentages of S. flexneri subserotypes were significantly different only for S. flexneri 1b, S. flexneri 2b, S. flexneri 6, and S. flexneri X. The proportion of isolates that were S. flexneri plus S. sonnei by year of the study at all sites, Bangladesh, and the 6 sites other than Bangladesh is shown in Table 2. Remarkably, there was little variation.
Table 2.
Prevalence of Shigella sonnei and S. flexneri Serogroups and Proposed Vaccine Component Serotypes of S. flexneri Among Shigella Isolates From Global Enteric Multicenter Study Cases by Year of the Study
| All 7 GEMS Sites |
6 GEMS Sites Other Than Bangladesh |
Bangladesh |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Serogroup, Serotype, or Subserotype | Year 1 | Year 2 | Year 3 | Year 1 | Year 2 | Year 3 | Year 1 | Year 2 | Year 3 |
| Total isolates | 457 | 345 | 328 | 214 | 142 | 163 | 243 | 203 | 165 |
| S. sonnei | 94 (20.6%)a | 76 (22.0%)a | 98 (29.9%)a | 53 (24.8%)b | 27 (19.0%)b | 39 (23.9%)b | 41 (16.9%)c | 49 (24.1%)c | 59 (35.8%)c |
| S. flexneri | 317 (69.4%)a | 231 (67.0%)a | 197 (60.1%)a | 134 (62.6%)b | 94 (66.2%)b | 102 (62.6%)b | 183 (75.3%)c | 137 (67.5%)c | 95 (57.6%)c |
| S. flexneri + S. sonnei | 411 (89.9%)a | 307 (89.0%)a | 295 (89.9%)a | 187 (87.4%)b | 121 (85.2)b | 141 (86.5%)b | 224 (92.2%)c | 186 (91.6%)c | 154 (93.3%)c |
| S. flexneri 2a, 3a and 6 | 183 | 144 | 131 | 97 | 54 | 67 | 86 | 90 | 64 |
| As % of all S. flexneri | 57.7%d | 62.3% | 66.5% | 72.4%e | 57.5% | 65.7% | 47.0%f | 65.7% | 67.4% |
| As % of all isolates | 40.0%a | 41.7% | 39.9% | 45.3%b | 38.0% | 41.1% | 35.4%c | 44.3% | 38.8% |
| S. sonnei + S. flexneri 2a, 3a and 6 | 277 (60.6%)a | 220 (63.8%) | 229 (69.8%) | 150 (70.1%)b | 81 (57.0%) | 106 (65.0%) | 127 (52.3%)c | 139 (68.5%) | 123 (74.6%) |
| S. sonnei + all S. flexneri serotypes other than S. flexneri 7a | 403 (88.2%)a | 296 (85.8%) | 291 (88.7%) | 182 (85.1%)b | 116 (81.7%) | 138 (84.7%) | 221 (91.0%)c | 180 (88.7%) | 153 (92.7%) |
Abbreviation: GEMS, Global Enteric Multicenter Study.
a Percent of all case isolates for particular study year for all 7 GEMS sites.
b Percent of all case isolates for particular study year for 6 GEMS sites other than Bangladesh.
c Percent of all case isolates for particular study year for Bangladesh.
d Percent of all S. flexneri isolates for particular study year for all 7 GEMS sites.
e Percent of all S. flexneri isolates for particular study year for 6 GEMS sites other than Bangladesh.
f Percent of all S. flexneri isolates for particular study year for Bangladesh.
Among 219 isolates from control subjects (Table 1), there was less representation of S. flexneri (N = 115; 52.5%) compared with cases, where 65.9% of all isolates were S. flexneri (P < .001). Shigella flexneri 2a, S. flexneri 2b, S. flexneri 3a, and S. flexneri 6 accounted for 78.0% of S. flexneri case isolates vs 71.3% of control S. flexneri isolates. Shigella flexneri 2a ranked first in frequency followed by S. flexneri 6 among cases; among controls, S. flexneri 6 ranked first followed by S. flexneri 2a.
There was excellent concordance between CVD and CDC results in serotyping quality control. The 46 S. dysenteriae isolates sent by CVD were confirmed by CDC as S. dysenteriae serotypes 2 (N = 17), 3 (N = 10), 4 (N = 12), 8 (N = 1), 9 (N = 1), and 12 (N = 5). CDC confirmed 76 of 77 putative S. boydii that they serotyped as S. boydii 1 (N = 11), 2 (N = 16), 3 (N = 1), 4 (N = 16), 5 (N = 1), 7 (N = 1), 8 (N = 4), 10 (N = 9), 11 (N = 1), 12 (N = 4), 14 (N = 3), 15 (N = 2), 18 (N = 3), and 20 (N = 5); the remaining isolate was Escherichia albertii, which is known to share O antigens with S. boydii 13 [31]. Of 37 putative S. sonnei isolates, 36 were confirmed and 1 was found by CDC to be S. dysenteriae-like provisional serotype 96–3162 serotype. CDC confirmed CVD's subserotyping of 146 of the 147 S. flexneri sent, the exception being a strain identified by CVD as S. flexneri 1b but shown by CDC to be S. dysenteriae 3 (strain mix-up). Finally, 22 Shigella isolates sent by CVD were deemed untypable with available reagents. CDC identified 21 of the 22; 20 were S. dysenteriae-like provisional serotype 96–3162 and 1 was S. boydii-like provisional serotype 2009C-3081.
ShET1, a classic enterotoxin consisting of 1 enzymatically active A subunit linked to 5 binding B subunits, is encoded by setAB [26, 32] located within chromosomal Shigella pathogenicity island 1 [26, 32], originally identified in S. flexneri 2a. Notably, 85 of 86 GEMS S. flexneri 2a tested positive for ShET1, as did all 33 S. flexneri 2b strains tested. Only 4 of 134 (3.0%) isolates of other S. flexneri serotypes were positive, including 2/2 S. flexneri 5b, 1/1 S. flexneri Y, and 1/22 S. flexneri 3a.
DISCUSSION
Natural immunity to Shigella is largely based on immune responses to O antigens. Follow-up of a Chilean pediatric cohort where S. sonnei, S. flexneri 2a, and S. flexneri 6 were the most prevalent serotypes (79% of cases) indicated that an initial episode of shigellosis conferred approximately 75% protection against subsequent shigellosis due to the same serotype but did not significantly cross protect against illness caused by the other predominant serotypes [12]. Seroepidemiological studies from Israel corroborate the importance of preexistent O antibody (denoting prior exposure) in lowering the risk of S. sonnei and S. flexneri 2a disease [13, 14]. Accordingly, developers of vaccines to prevent shigellosis have designed serotype-based vaccines [4, 6], some of which have conferred significant protection [9, 15–20, 33].
One obstacle to developing serotype-based Shigella vaccines is choosing the minimal number from among 50 serotypes. The more serotypes included, the more complex and expensive the vaccine, leading some investigators to pursue common protein vaccines [34]. However, the extensive GEMS serotype data from multiple locations over several years constitutes a hallmark resource to guide vaccine development and provides optimism for serotype-based vaccines.
During GEMS, the fearsome S. dysenteriae 1 serotype, which caused protracted pandemics of severe disease from the 1960s to the1990s in Central America [35], Asia [36], and Africa [37, 38], was not isolated nor were there S. dysenteriae 1 outbreaks reported during 2006–2013. This suggests one may exclude S. dysenteriae 1 from a multivalent vaccine to prevent endemic shigellosis in developing countries. Nevertheless, should public health authorities deem it critical that a S. dysenteriae 1 vaccine be available for future resurgences of pandemic Shiga dysentery, a monovalent vaccine could be stockpiled [39]. Since absence of Shiga disease precludes a controlled field trial, prelicensure efficacy must be demonstrated in alternative ways (eg, volunteer challenges with a nontoxigenic strain) [40].
Although S. dysenteriae has 15 and S. boydii has 19 distinct serotypes, they accounted for only 5.0% and 5.4%, respectively, of all Shigella case isolates. Assuming distributions do not change dramatically over longer time periods, excluding these serotypes from a vaccine would have little impact on breadth of coverage. In contrast, S. flexneri serotypes/subserotypes comprised 65.9% of all Shigella case isolates, making it imperative that coverage be provided against the most important S. flexneri subserotypes. Interestingly, a mere 5 of the 15 currently recognized S. flexneri serotypes/subserotypes accounted for 89.4% of S. flexneri isolates, including (in rank order) S. flexneri 2a, S. flexneri 6, S. flexneri 2b, S. flexneri 3a, and S. flexneri 1b. Nevertheless, the relative distribution of S. flexneri subserotypes may change over time in various geographic locales. Thus, it will be prudent for Shigella vaccines to provide coverage against all 15 S. flexneri serotypes/subserotypes.
CVD investigators devised a strategy to achieve broad-spectrum coverage against all S. flexneri serotypes except uncommon S. flexneri 7a by presenting to the immune system a mix of the following 3 serotypes: S. flexneri 2a, S. flexneri 3a, and S. flexneri 6 [6, 41]. Shigella flexneri 6 is common, and its O antigen is distinct from other S. flexneri. Indeed, genomic evidence indicates S. flexneri 6 might more appropriately be classified as a S. boydii serotype; however, for historical and practical reasons, it retains designation as a S. flexneri serotype.
Shigella flexneri serotypes/subserotypes other than S. flexneri 6 have O antigens that share a common backbone structure that consists of tetrasaccharide repeats of 3 rhamnose residues linked to 1 N-acetylglucosamine [6]. Genes encoding the enzymes that synthesize the tetrasaccharide backbone reside in the S. flexneri chromosomal rfb locus. Shigella flexneri Y's O antigen consists of tetrasaccharide repeats without further modifications. However, lysogenic bacteriophages that encode enzymes able to decorate the tetrasaccharide backbone at specific sites with O-acetyl or D-glucose moieties create new epitopes or ablate others and result in modified saccharide structures that represent the other S. flexneri serotypes [6]. The epitopes created by these O-acetyl and D-glucose groups also constitute group antigens shared among different S. flexneri serotypes. If the shared group and type-specific antigens induce cross-protective immunity, the number of subserotypes required for a broadly effective Shigella vaccine can be minimized. Thus, a multivalent vaccine that includes S. flexneri 2a and S. flexneri 3a (Table 3), in addition to cross protecting against S. flexneri 2b (via type 2 antigen) and S. flexneri 3b (via type 3 antigen), would provide shared group antigens that could elicit cross protection against S. flexneri 1a, 3b, 4a, 5a, and Y (via group antigen 3,4); against S. flexneri 1b, 3b, 4b, and 7b (via group antigen 6); and against S. flexneri 2b, 5b, and X (via group 7,8). No cross protection could accrue against S. flexneri 6, as its O tetrasaccharide structure (rhamnose-rhamnose-D-galactose-N-acetylgalactosamine) is distinct and lacks the group antigens shared by other S. flexneri serotypes.
Table 3.
Twelve Serotypes and Subserotypes of Shigella flexneri Not in the Quadrivalent Vaccine and O Group Antigens That They Share With the Vaccine Serotypes
| Serotypes in the Quadrivalent Shigella Vaccine (and their O antigens) | 12 Serotypes and Subserotypes of S. flexneri Not in the Quadrivalent Vaccine |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1a | 1b | 2b | 3b | 4a | 4b | 5a | 5b | 7a | 7b | X | Y | |
| S. flexneri 2a (type antigen II and group antigen “3,4”) | Group antigen “3,4”a | Type antigen IIa | Group antigen “3,4”a | Group antigen “3,4”a | Group antigen “3,4”a | … | Group antigen “3,4”a | |||||
| S. flexneri 3a (type antigen III and group antigens “6” and “7,8”) | Group antigen “6”a | Group antigen “7,8”a | Type antigen IIIa | Group antigen “6”a | Group antigen “7,8”a | … | Group antigen “6”a | Group antigen “7,8”a | ||||
| S. flexneri 6 (type antigen VI) | … | … | … | … | … | … | … | … | … | … | … | … |
a S. flexneri type and group antigens that are shared with the S. flexneri serotypes/subserotypes that are in the vaccine and that constitute the immunologic basis for cross protection.
Noriega et al [41] used the guinea pig Sereny keratoconjunctivitis model to measure cross-reacting serological responses and cross protection when animals immunized mucosally with a live bivalent vaccine containing S. flexneri 2a and S. flexneri 3a were challenged with other S. flexneri subserotypes. Significant cross protection was demonstrated against challenge with heterologous serotypes/subserotypes including S. flexneri Y, 1b, 2b, and 5b; protection against S. flexneri 1a was borderline (P = .065). As expected, no cross protection was observed in immunized animals challenged with S. flexneri 6 [41].
Following S. flexneri 2a illness or vaccination with live oral vaccine expressing S. flexneri 2a O antigen, the human immune system mounts cross-reacting antibody responses against other S. flexneri serotypes that share type or group antigens [42]. If the cross protection observed in animals can be extrapolated to humans, a multivalent vaccine that includes O antigens of S. sonnei, S. flexneri 2a, S. flexneri 3a, and S. flexneri 6 would provide direct coverage against approximately 64% of the GEMS Shigella strains, and cross protection could provide up to 88% overall coverage. Indeed, only S. flexneri 7a (merely 2.0% of GEMS isolates) lacks any of the mentioned shared group antigens; S. flexneri 7b expresses group antigen 6. Excluding S. flexneri 7a from a multivalent vaccine would have little impact on global breadth of coverage.
Table 2 displays GEMS serotypes in relation to the proposed quadrivalent vaccine composition (S. flexneri 2a, S. flexneri 3a, S. flexneri 6 plus S. sonnei) to estimate breadth of coverage and possible variation over time from the perspective of all 7 GEMS sites, the site with the most Shigella cases (Bangladesh), and the other 6 sites. Only minimal changes in serotypes are seen from year to year; matching of serotypes between circulating strains and vaccine composition would provide 52%–75% direct protection and, with shared group antigens, 82%–93% coverage can be achieved via cross protection.
One other multicenter study used systematic surveillance to detect Shigella cases, quantify the burden of shigellosis, and identify serotypes [2]. Von Seidlein et al [2] used a different definition of diarrheal illness as the eligibility criterion for enrollment, obtained strains from older subjects as well as children aged <5 years, maintained surveillance for different time periods (1–3 years, depending on the site), and worked only in Asia (China, Thailand, Vietnam, Indonesia, Bangladesh, and Pakistan) but used microbiological methods similar to GEMS and similarly included sites in Pakistan and Bangladesh. Among the total 2927 Shigella isolates reported by Von Seidlein et al [2], 90% were either S. flexneri (68%) or S. sonnei (22%), similar to GEMS; 51% of their S. flexneri isolates were S. flexneri 2a, S. flexneri 3a, or S. flexneri 6. Importantly, like GEMS, they found no S. dysenteriae 1 among their 110 S. dysenteriae isolates [2]. Via direct or via shared group antigens, the quadrivalent vaccine would cover at least 84.7% of the 2819 fully serotyped Shigella strains isolated by Von Seidlein et al [2].
Preclinical and clinical evidence indicates that ShET1 contributes to the watery diarrhea observed early in S. flexneri 2a clinical illness and to diarrheal adverse reactions associated with certain live oral vaccines [26, 27, 43]; deleting set and sen diminishes vaccine reactogenicity [43, 44]. We confirmed that ShET1 genes are common in S. flexneri 2a and 2b isolates (117/119, 98.3%) but rare among other S. flexneri subserotypes (4/137, 2.9%) or other species (2/132, 1.5%).
Serotyping of the GEMS Shigella isolates offers optimism that a quadrivalent vaccine containing S. sonnei and 3 serotype/subserotypes of S. flexneri (S. flexneri 2a, S. flexneri 3a, and S. flexneri 6) can provide broad coverage against Shigella, which causes the majority of endemic pediatric shigellosis in the developing world, and also can provide broad coverage for travelers [45, 46].
Notes
Acknowledgments. The authors acknowledge the exceptional serotyping prowess of Ms Evangeline Sowers at the Centers for Disease Control and Prevention (CDC).
Disclaimer. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the CDC.
Financial support. This work was supported by grant 38774 from the Bill & Melinda Gates Foundation to M. M. L.
Potential conflicts of interest. All authors: No potential conflicts of interest.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
References
- 1.Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013;382:209–22. doi: 10.1016/S0140-6736(13)60844-2. [DOI] [PubMed] [Google Scholar]
- 2.von Seidlein L, Kim DR, Ali M, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLos Med. 2006;3:e353. doi: 10.1371/journal.pmed.0030353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Lindsay B, Ochieng JB, Ikumapayi UN, et al. Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries. J Clin Microbiol. 2013;51:1740–6. doi: 10.1128/JCM.02713-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Barry EM, Pasetti MF, Sztein MB, Fasano A, Kotloff KL, Levine MM. Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol. 2013;10:245. doi: 10.1038/nrgastro.2013.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Levine MM. Enteric infections and the vaccines to counter them: future directions. Vaccine. 2006;24:3865–73. doi: 10.1016/j.vaccine.2006.03.039. [DOI] [PubMed] [Google Scholar]
- 6.Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol. 2007;5:540–53. doi: 10.1038/nrmicro1662. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Foster RA, Carlin NI, Majcher M, Tabor H, Ng LK, Widmalm G. Structural elucidation of the O-antigen of the Shigella flexneri provisional serotype 88–893: structural and serological similarities with S. flexneri provisional serotype Y394 (1c) Carbohydr Res. 2011;346:872–6. doi: 10.1016/j.carres.2011.02.013. [DOI] [PubMed] [Google Scholar]
- 8.Formal SB, Oaks EV, Olsen RE, Wingfield Eggleston M, Snoy PJ, Cogan JP. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J Infect Dis. 1991;164:533–7. doi: 10.1093/infdis/164.3.533. [DOI] [PubMed] [Google Scholar]
- 9.DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis. 1972;125:12–6. doi: 10.1093/infdis/125.1.12. [DOI] [PubMed] [Google Scholar]
- 10.Herrington DA, Van de Verg L, Formal SB, et al. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine. 1990;8:353–7. doi: 10.1016/0264-410x(90)90094-3. [DOI] [PubMed] [Google Scholar]
- 11.Kotloff KL, Nataro JP, Losonsky GA, et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine. 1995;13:1488–94. doi: 10.1016/0264-410x(95)00102-7. [DOI] [PubMed] [Google Scholar]
- 12.Ferreccio C, Prado V, Ojeda A, et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in a poor periurban setting in Santiago, Chile. Am J Epidemiol. 1991;134:614–27. doi: 10.1093/oxfordjournals.aje.a116134. [DOI] [PubMed] [Google Scholar]
- 13.Cohen D, Green MS, Block C, Slepon R, Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol. 1991;29:386–9. doi: 10.1128/jcm.29.2.386-389.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Cohen D, Green MS, Block C, Rouach T, Ofek I. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis. 1988;157:1068–71. doi: 10.1093/infdis/157.5.1068. [DOI] [PubMed] [Google Scholar]
- 15.Mel DM, Terzin AL, Vuksic L. Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull WHO. 1965;32:647–55. [PMC free article] [PubMed] [Google Scholar]
- 16.Mel DM, Arsic BL, Nikolic BD, Radovanovic ML. Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines. Bull WHO. 1968;39:375–80. [PMC free article] [PubMed] [Google Scholar]
- 17.Mel DM, Gangarosa EJ, Radovanovic ML, Arsic BL, Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull WHO. 1971;45:457–64. [PMC free article] [PubMed] [Google Scholar]
- 18.Mel DM, Arsic BL, Radovanovic ML, Litvinjenko S. Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbiol Acad Sci Hung. 1974;21:109–14. [PubMed] [Google Scholar]
- 19.Cohen D, Ashkenazi S, Green MS, et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet. 1997;349:155–9. doi: 10.1016/S0140-6736(96)06255-1. [DOI] [PubMed] [Google Scholar]
- 20.Passwell JH, Ashkenzi S, Banet-Levi Y, et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1–4-year-old Israeli children. Vaccine. 2010;28:2231–5. doi: 10.1016/j.vaccine.2009.12.050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Levine MM, Kotloff KL, Nataro JP, Muhsen K. The Global Enteric Multicenter Study (GEMS): Impetus, rationale, and genesis. Clin Infect Dis. 2012;55(suppl 4):S215–24. doi: 10.1093/cid/cis761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Panchalingam S, Antonio M, Hossain A, et al. Diagnostic microbiologic methods in the GEMS-1 case/control study. Clin Infect Dis. 2012;55(suppl 4):S294–302. doi: 10.1093/cid/cis754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Farag TH, Nasrin D, Wu Y, et al. Some epidemiologic, clinical, microbiologic, and organizational assumptions that influenced the design and performance of the Global Enteric Multicenter Study (GEMS) Clin Infect Dis. 2012;55(suppl 4):S225–31. doi: 10.1093/cid/cis787. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kotloff KL, Blackwelder WC, Nasrin D, et al. The Global Enteric Multicenter Study (GEMS) of diarrheal disease in infants and young children in developing countries: epidemiologic and clinical methods of the case/control study. Clin Infect Dis. 2012;55(suppl 4)):S232–45. doi: 10.1093/cid/cis753. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Morris GK, Koehler JA, Gangarosa EJ, Sharrar RG. Comparison of media for direct isolation and transport of Shigellae from fecal specimens. Appl Microbiol. 1970;19:434–7. doi: 10.1128/am.19.3.434-437.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Fasano A, Noriega FR, Maneval DR, Jr, et al. Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest. 1995;95:2853–61. doi: 10.1172/JCI117991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Fasano A, Noriega FR, Liao FM, Wang W, Levine MM. Effect of Shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo. Gut. 1997;40:505–11. doi: 10.1136/gut.40.4.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Noriega FR, Liao FM, Formal SB, Fasano A, Levine MM. Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes. J Infect Dis. 1995;172:1408–10. doi: 10.1093/infdis/172.5.1408. [DOI] [PubMed] [Google Scholar]
- 29.Roy S, Thanasekaran K, Dutta Roy AR, Sehgal SC. Distribution of Shigella enterotoxin genes and secreted autotransporter toxin gene among diverse species and serotypes of Shigella isolated from Andaman Islands, India. Trop Med Int Health. 2006;11:1694–8. doi: 10.1111/j.1365-3156.2006.01723.x. [DOI] [PubMed] [Google Scholar]
- 30.Farag TH, Faruque AS, Wu Y, et al. Housefly population density correlates with shigellosis among children in Mirzapur, Bangladesh: a time series analysis. PLoS Negl Trop Dis. 2013;7:e2280. doi: 10.1371/journal.pntd.0002280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Hyma KE, Lacher DW, Nelson AM, et al. Evolutionary genetics of a new pathogenic Escherichia species: Escherichia albertii and related Shigella boydii strains. J Bacteriol. 2005;187:619–28. doi: 10.1128/JB.187.2.619-628.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Al-Hasani K, Rajakumar K, Bulach D, Robins-Browne R, Adler B, Sakellaris H. Genetic organization of the she pathogenicity island in Shigella flexneri 2a. Microb Pathog. 2001;30:1–8. doi: 10.1006/mpat.2000.0404. [DOI] [PubMed] [Google Scholar]
- 33.Coster TS, Hoge CW, Van DeVerg LL, et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun. 1999;67:3437–43. doi: 10.1128/iai.67.7.3437-3443.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, et al. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun. 2012;80:1222–31. doi: 10.1128/IAI.06174-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Gangarosa EJ, Perera DR, Mata LJ, Mendizabal-Morris C, Guzman G, Reller LB. Epidemic Shiga bacillus dysentery in Central America. II. Epidemiologic studies in 1969. J Infect Dis. 1970;122:181–90. doi: 10.1093/infdis/122.3.181. [DOI] [PubMed] [Google Scholar]
- 36.Rahaman MM, Khan MM, Aziz KMS, Islam MS, Kibriya AK. An outbreak of dysentery caused by Shigella dysenteriae type 1 on a Coral Island in the Bay of Bengal. J Infect Dis. 1975;132:15–9. doi: 10.1093/infdis/132.1.15. [DOI] [PubMed] [Google Scholar]
- 37.Ebright JR, Moore EC, Sanborn WR, Schaberg D, Kyle J, Ishida K. Epidemic Shiga bacillus dysentery in Central Africa. Am J Trop Med Hyg. 1984;33:1192–7. doi: 10.4269/ajtmh.1984.33.1192. [DOI] [PubMed] [Google Scholar]
- 38.Birmingham ME, Lee LA, Ntakibirora M, Bizimana F, Deming MS. A household survey of dysentery in Burundi: implications for the current pandemic in sub-Saharan Africa. Bull World Health Organ. 1997;75:45–53. [PMC free article] [PubMed] [Google Scholar]
- 39.Martin S, Costa A, Perea W. Stockpiling oral cholera vaccine. Bull World Health Organ. 2012;90:714. doi: 10.2471/BLT.12.112433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Samandari T, Kotloff KL, Losonsky GA, et al. Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a shiga toxin-deleted Shigella dysenteriae type 1 strain. J Immunol. 2000;164:2221–32. doi: 10.4049/jimmunol.164.4.2221. [DOI] [PubMed] [Google Scholar]
- 41.Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM. Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun. 1999;67:782–8. doi: 10.1128/iai.67.2.782-788.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Van de Verg LL, Bendiuk NO, Kotloff K, et al. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. Vaccine. 1996;14:1062–8. doi: 10.1016/0264-410x(96)00006-0. [DOI] [PubMed] [Google Scholar]
- 43.Kotloff KL, Pasetti MF, Barry EM, et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis. 2004;190:1745–54. doi: 10.1086/424680. [DOI] [PubMed] [Google Scholar]
- 44.Kotloff KL, Simon JK, Pasetti MF, et al. Safety and immunogenicity of CVD 1208S, a live, oral ÄguaBA Äsen Äset Shigella flexneri 2a vaccine grown on animal-free media. Human Vaccines. 2007;3:268–75. doi: 10.4161/hv.4746. [DOI] [PubMed] [Google Scholar]
- 45.Hyams KC, Bourgeois AL, Merrell BR, et al. Diarrheal disease during Operation Desert Shield. N Engl J Med. 1991;325:1423–8. doi: 10.1056/NEJM199111143252006. [DOI] [PubMed] [Google Scholar]
- 46.Thornton SA, Sherman SS, Farkas T, Zhong W, Torres P, Jiang X. Gastroenteritis in US marines during Operation Iraqi Freedom. Clin Infect Dis. 2005;40:519–25. doi: 10.1086/427501. [DOI] [PubMed] [Google Scholar]